Isofol Medical AB ( (SE:ISOFOL) ) has issued an announcement.
Isofol Medical AB has initiated a clinical phase Ib/II study for arfolitixorin, a potential new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the drug’s efficacy as part of standard first-line therapy, marking a significant milestone towards market readiness and offering hope for improved patient outcomes.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe cancer forms. Their drug candidate, arfolitixorin, aims to enhance the efficacy of first-line standard treatments for solid tumors, with current studies targeting colorectal cancer, the third most common cancer globally.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.